Compare · GILD vs KYTX
GILD vs KYTX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Kyverna Therapeutics Inc. (KYTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and KYTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.82B, about 326.5x KYTX ($477.2M).
- Over the past year, GILD is up 14.0% and KYTX is up 117.9% - KYTX leads by 104.0 points.
- GILD has been more active in the news (20 items in the past 4 weeks vs 11 for KYTX).
- GILD has more recent analyst coverage (25 ratings vs 9 for KYTX).
- Company
- Gilead Sciences Inc.
- Kyverna Therapeutics Inc.
- Price
- $125.46-2.11%
- $7.83+1.62%
- Market cap
- $155.82B
- $477.2M
- 1M return
- -4.46%
- -16.11%
- 1Y return
- +13.97%
- +117.94%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2024
- News (4w)
- 20
- 11
- Recent ratings
- 25
- 9
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Latest KYTX
- Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
- Kyverna Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Cohen Fred E was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)
- Director Clark Ian T was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)
- Director Seidenberg Beth C was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)
- Executive Chairperson Shaw Christi covered exercise/tax liability with 4,194 shares, decreasing direct ownership by 6% to 66,741 units (SEC Form 4) to cover taxes
- Director Aktar Mert was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)
- SEC Form 3 filed by new insider Martini Gregory S.
- SEC Form 4 filed by Chief Financial Officer Martini Gregory S.
- Kyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits